Genes and pathways involved in inflammatory response, obesity, diabetes, and heart disease

The provided term refers to a broad set of interconnected biological processes rather than a single, discrete therapeutic target. These pathways involve a complex network of genes and proteins, such as pro-inflammatory cytokines (e.g., TNF, IL-6), transcription factors (e.g., NF-kappaB), and metabolic regulators (e.g., PPARs), which collectively mediate the link between chronic inflammation and metabolic syndromes (Hotamisligil, G. S., Nature, 2006). In the context of obesity and diabetes, adipose tissue dysfunction often triggers systemic inflammation, which in turn promotes insulin resistance and accelerates the progression of atherosclerosis and heart disease (NIH, National Heart, Lung, and Blood Institute). Because this entry describes a multi-faceted physiological and pathological landscape, it is considered incorrect as a specific target name for drug development. Therapeutic intervention typically requires focusing on specific, well-defined nodes within these pathways, such as the GLP-1 receptor for metabolic control or specific interleukins for reducing cardiovascular risk (Ridker et al., New England Journal of Medicine, 2017). Consequently, this entry represents a research area or a disease-pathway association rather than a druggable molecular entity. Understanding these pathways is crucial for identifying novel biomarkers and multi-target strategies to treat comorbid metabolic and cardiovascular conditions.

Other names

Metabolic-inflammatory pathwaysMeta-inflammationChronic low-grade inflammation pathwaysInflammatory-metabolic axis

Not applicable as this entry describes a broad category of biological pathways rather than a single, discrete molecular target.